Phase I study of BAY 73-4506, an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors: Final results of a dose-escalation study

被引：0
|
作者：
Frost, A.
Buechert, M.
Unger, C.
Christensen, O.
Wagner, A.
Heinig, R. A.
Scheulen, M. E.
Strumberg, D.
Fasol, U.
Mross, K.
机构：
[1] Tumor Biol Ctr, Freiburg, Germany
[2] Univ Hosp Freiburg, Freiburg, Germany
[3] Bayer HealthCare Pharmaceut, West Haven, CT USA
[4] Bayer Schering Pharma AG, Berlin, Germany
[5] Bayer HealthCare, Wuppertal, Germany
[6] Univ Essen Gesamthsch, Sch Med, Essen, Germany
[7] Univ Hosp Bochum, Marienhosp Herne, Herne, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2558
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A Phase I Dose-Escalation Study of Regorafenib (BAY 73-4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors
    Mross, Klaus
    Frost, Annette
    Steinbild, Simone
    Hedbom, Susanne
    Buechert, Martin
    Fasol, Ulrike
    Unger, Clemens
    Kraetzschmar, Joern
    Heinig, Roland
    Boix, Oliver
    Christensen, Olaf
    CLINICAL CANCER RESEARCH, 2012, 18 (09) : 2658 - 2667
  • [2] Phase I dose-escalation study of continuously administered regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors.
    Shimizu, T.
    Tolcher, A. W.
    Patnaik, A.
    Papadopoulos, K.
    Christensen, O.
    Lin, T.
    Blumenschein, G. R., Jr.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] Phase I trial of BAY 73-4506, a kinase inhibitor that targets oncogenic and angiogenic kinases, in patients with advanced solid tumors.
    Frost, A.
    Hedbom, S.
    Steinbild, S.
    Buchert, M.
    Unger, C.
    Christensen, O.
    Voliotis, D.
    Heinig, R.
    Mross, K.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3459S - 3460S
  • [4] Phase I study of BAY 73-4506, an inhibitor of oncogenic and angiogenic kinases, in patients with advanced refractory colorectal carcinoma (CRC)
    Strumberg, D.
    Scheulen, M. E.
    Frost, A.
    Buchert, M.
    Christensen, O.
    Wagner, A.
    Heinig, R.
    Fasol, U.
    Mross, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] Phase I study of BAY 73-4506, a multikinase inhibitor, administered for 21 days on/7 days off in patients with advanced solid tumors
    Hedbom, S.
    Steinbild, S.
    Frost, A.
    Buechert, M.
    Unger, C.
    Christensen, O.
    Kornacker, M.
    Voliotis, D.
    Heinig, R.
    Mross, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] Phase I study of regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, administered continuously in patients (pts) with advanced refractory non-small cell lung cancer (NSCLC).
    Kies, M. S.
    Blumenschein, G. R., Jr.
    Christensen, O.
    Lin, T.
    Tolcher, A. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [7] Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study
    D Strumberg
    M E Scheulen
    B Schultheis
    H Richly
    A Frost
    M Büchert
    O Christensen
    M Jeffers
    R Heinig
    O Boix
    K Mross
    British Journal of Cancer, 2012, 106 : 1722 - 1727
  • [8] Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study
    Strumberg, D.
    Scheulen, M. E.
    Schultheis, B.
    Richly, H.
    Frost, A.
    Buechert, M.
    Christensen, O.
    Jeffers, M.
    Heinig, R.
    Boix, O.
    Mross, K.
    BRITISH JOURNAL OF CANCER, 2012, 106 (11) : 1722 - 1727
  • [9] Preclinical characterization of BAY 73-4506: A kinase inhibitor with broad spectrum antitumor activity targeting oncogenic and angiogenic kinases
    Wilhelm, Scott
    Adnane, Lila
    Hirth-Dietrich, Claudia
    Ehrlich, Paul
    Lynch, Mark
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3514S - 3514S
  • [10] Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors
    Sun, Yongkun
    Yang, Lin
    Hao, Xuezhi
    Liu, Yutao
    Zhang, Jinwen
    Ning, Zhiqiang
    Shi, Yuankai
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (1)
12345